Detail akcie Circassia online

Business Summary: NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The Company's NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Niox Group PLC revenues increased 12% to L21M. Net income before extraordinary items increased 52% to L4.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from operating-NIOX segment income increase of 24% to L6.1M. Basic Earnings per Share excluding Extraordinary Items remained flat at L0.01.